Vera Therapeutics/$VERA
Vera Therapeutics shares rise after TRUTAKNA met all prespecified endpoints in the final Phase 3 ORIGIN 3 analysis, stabilising kidney function and preventing disease progression in IgA nephropathy.
1 hour agoLightyear AI
1D1W1MYTD1Y5YMAX
Capital at risk
About Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
- Ticker
- $VERA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 361
- Headquarters
- Brisbane, United States
- Website
- veratx.com
VERA Metrics
BasicAdvanced
$2.3B
-
-$5.89
0.95
-
Price and volume
Market cap
$2.3B
Beta
0.95
52-week high
$56.05
52-week low
$23.05
Average daily volume
2.4M
Financial strength
Current ratio
10.916
Quick ratio
10.411
Long term debt to equity
0.189
Total debt to equity
0.189
Interest coverage (TTM)
-55.18%
Profitability
EBITDA (TTM)
-415.224
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-46.76%
Return on equity (TTM)
-91.75%
Valuation
Price to book
5.61
Price to tangible book (TTM)
5.62
Price to free cash flow (TTM)
-6.388
Free cash flow yield (TTM)
-15.65%
Free cash flow per share (TTM)
-4.973
Growth
Earnings per share change (TTM)
64.06%
3-year earnings per share growth (CAGR)
23.41%
What the Analysts think about VERA
Analyst ratings (Buy, Hold, Sell) for Vera Therapeutics stock.
Analyst projections of the future price of Vera Therapeutics stock.
Bulls say / Bears say
Final ORIGIN 3 data met all prespecified endpoints, including kidney-function and disease-progression measures, while the safety profile was generally comparable with placebo. This materially strengthens the case that TRUTAKNA could offer disease modification rather than only a reduction in proteinuria. (Vera Therapeutics)
The FDA granted TRUTAKNA accelerated approval in July 2026, making it the first approved treatment to inhibit both BAFF and APRIL in IgA nephropathy. This gives Vera an immediate commercial opportunity while it seeks to convert the approval into a full authorisation. (GlobeNewswire)
Vera generated more than 350 patient start forms in the first ten weeks of launch, alongside paid claims and encouraging early payer policies. That suggests genuine initial demand and gives the company a foundation from which to build recurring product revenue. (Vera Therapeutics)
TRUTAKNA still has accelerated rather than full FDA approval, and its current label is based on proteinuria reduction. Continued approval remains contingent on verification of clinical benefit, with Vera only planning to file the supplemental application in the fourth quarter and targeting a possible full approval in 2027. (Vera Therapeutics)
The IgA nephropathy market is becoming crowded, with Otsuka’s Voyxact reporting positive two-year data and Vertex advancing the competing dual BAFF/APRIL inhibitor povetacicept towards a regulatory decision. Existing treatments such as Tarpeyo and Filspari add further pressure, while Vera has no head-to-head evidence proving superiority. (Clinical Trials Arena, Longbridge)
Vera reported a $109.5 million second-quarter net loss and $206.8 million of operating cash outflow in the first half of 2026, while cash and marketable securities fell to $499.2 million. Management says it may need further financing, so a slower-than-expected launch could create additional debt or dilution pressure. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
VERA Financial Performance
Revenues and expenses
VERA Earnings Performance
Company profitability
Upcoming events
No upcoming events
VERA News
AllArticlesVideos
Funds containing VERA
AllGBPUSDEUR
Fund name | Fund size | $VERA weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.70% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.17% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.17% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.07% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.